source
- Lilly to buy startup Ajax in bid for a better JAK drugWorth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.BioPharma Dive · 3mo ago↗ source
- Oruka posts Phase 2 win in psoriasis, hoping to compete with SkyriziOruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…Endpoints · 3mo ago↗ source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorderThe findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.